P38 can activate MAPK to promote tumour progression.36 As the main downstream effector of PI3K, AKT is often dysregulated in tumour progression.37 Drugs targeting PI3K or AKT have been developed for tumour treatment.38 After the overexpression of TPPP, we found that the phosphorylation of p38/MAPK and PI3K/AKT were increased. This evidence concerns the gene AKT1 and neoplasm.